157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer
Open Access
- 1 September 2003
- journal article
- abstracts
- Published by Elsevier in European Journal of Cancer Supplements
- Vol. 1 (5) , S51
- https://doi.org/10.1016/s1359-6349(03)90190-x
Abstract
No abstract availableThis publication has 0 references indexed in Scilit: